Save 40% on Vosevi from Europe
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Manufacturer for Europe:
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
Information about Vosevi (Sofosbuvir / Velpatasvir / Voxilaprevir)
Vosevi is a combination medication used for the treatment of chronic hepatitis C. It contains three active ingredients: Sofosbuvir, Velpatasvir, and Voxilaprevir, which work together to target and inhibit the hepatitis C virus (HCV) at different stages of its replication cycle. By blocking multiple steps in the HCV lifecycle, Vosevi helps to stop the virus from multiplying, leading to improved liver function and a potential cure for HCV.
Product Highlights
- Vosevi is used for the treatment of chronic hepatitis C in adults, specifically for those with HCV genotypes 1, 2, 3, or 4.
- It is particularly indicated for patients who have previously been treated with other direct-acting antiviral (DAA) therapies, including those who failed to achieve sustained virologic response (SVR) or had a relapse.
- Vosevi is also indicated for patients with chronic hepatitis C who are coinfected with HIV-1 and have not previously been treated with HCV treatments.
Key Ingredient
- Sofosbuvir
- Velpatasvir
- Voxilaprevir
Key Benefits
- Vosevi offers high cure rates in patients with chronic hepatitis C, especially in those who have failed previous treatments.
- It targets multiple stages of the hepatitis C virus lifecycle, which improves overall efficacy against different HCV genotypes.
- The medication is taken once daily, which increases patient adherence to treatment.
- Most patients experience mild side effects, and the medication is generally well-tolerated.
Direction of Use
- The usual recommended dosage is one tablet (400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir) taken once daily with or without food.
- The typical treatment duration is 12 weeks, but this can vary depending on factors such as HCV genotype and treatment history.
- The tablet should be swallowed whole. It should not be crushed or chewed.
- Safety Concerns
- Frequent side effects include headache, tiredness, nausea, and diarrhea. These are typically mild and resolve after a few days.
- Vosevi may interact with other medications, particularly those that affect liver enzymes (such as rifampin, carbamazepine, and phenytoin), as these can reduce the effectiveness of Vosevi.
- Vosevi should be used with caution in patients with severe liver disease, especially those with decompensated cirrhosis. Liver function should be monitored regularly.
- Resistance to the components of Vosevi can develop, so it is important to ensure the proper use of the medication and adherence to the prescribed regimen.
- For patients co-infected with HIV, careful monitoring is necessary, as drug interactions between Vosevi and antiretroviral therapy may occur.
Avoid Vosevi (Sofosbuvir / Velpatasvir / Voxilaprevir) If
- You have a severe allergic reaction (e.g., anaphylaxis) to any of the ingredients in Vosevi.
- You are taking certain medications that interfere with Vosevi’s efficacy, such as rifampin, carbamazepine, or phenytoin.
- You have severe liver problems (such as decompensated cirrhosis or liver failure).
- You are pregnant or plan to become pregnant, as Vosevi is not recommended during pregnancy unless specifically prescribed by a healthcare provider and the potential benefits outweigh the risks. It's important to use effective contraception during treatment.
- You are breastfeeding, as it’s unclear whether Vosevi passes into breast milk.
- You are taking p-glycoprotein inducers (like St. John’s wort), which may reduce the drug's effectiveness.
